The Diabetes Drug With an Accidental Cancer Benefit, and the Condition Where a Daily Aspirin Cuts Risk

Most cancer risk factors we've discussed in this series are broad and lifestyle-driven, smoking, weight, alcohol. This post covers two narrower, more specific stories, one genetic and rare, one a repurposed everyday drug, because both are underappreciated examples of how specific and actionable cancer prevention can get when the evidence is strong enough.

Lynch syndrome and aspirin, a genuinely striking result

Lynch syndrome is caused by inherited mutations in genes responsible for repairing DNA errors, and it substantially raises lifetime risk of colorectal cancer along with several other cancers, most notably endometrial cancer. It's estimated to affect a meaningful share of the population, though most carriers don't know they have it.

The CAPP2 trial, a randomized, placebo-controlled study, followed 861 people with Lynch syndrome for up to 20 years. Participants who took 600 mg of aspirin daily for at least two years showed a significantly reduced rate of colorectal cancer compared to placebo, roughly a 35% reduction in the main analysis, and the protective effect was still measurable two decades later even though the aspirin itself was only taken for a few years. A follow-up trial, CaPP3, is now testing whether lower daily doses, 100 mg or 300 mg, work as well as the original 600 mg, since lower doses carry less bleeding risk.

This is one of the clearest examples in all of oncology of a cheap, widely available drug producing a real, durable, randomized-trial-proven risk reduction in a specific high-risk population. It's not relevant to everyone, aspirin carries real bleeding risks and isn't advised as blanket cancer prevention for the general population, but for someone who knows they carry Lynch syndrome, this is a conversation worth having directly with a doctor.

Metformin's second job

Metformin is one of the oldest and most widely prescribed diabetes drugs, and separately from its blood sugar effects, it carries a long-standing observational association with reduced cancer incidence across several cancer types in people who take it. The proposed mechanism ties back to the same metabolic pathways we've discussed elsewhere in this series, tumors often rely heavily on glucose availability, and metformin affects how the body processes and stores glucose. This evidence is observational rather than from a dedicated randomized cancer-prevention trial, so it sits at a different, lower evidence tier than the Lynch syndrome and aspirin data, worth knowing about, not worth treating as proven the way CAPP2's results are. Blood sugar is one of the numbers the basic blood panel already gives you.

What this means practically

If you have a family history of early colorectal or endometrial cancer, particularly across multiple generations or at unusually young ages, ask your doctor about Lynch syndrome screening. It's identifiable through genetic testing, and if you carry it, the aspirin conversation is a real, evidence-backed one to have, not a fringe idea.

For everyone else, this is less about a specific action and more about the broader point this series keeps returning to: the most powerful interventions in medicine are often old, cheap, and already sitting in a medicine cabinet, not the newest thing being marketed to you.